PLK1 is elevated in prostate cancer and plays a role in coordinating the downstream PI3K-AKT-mTOR pathway and the activation of AR signaling through elevating cholesterol biosynthesis during the progression to castration-resistant disease [51]. Here, AR is linked to prostate carcinoma.